Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis
- 15 February 2016
- journal article
- review article
- Published by Spandidos Publications in Biomedical Reports
- Vol. 4 (4), 498-506
- https://doi.org/10.3892/br.2016.599
Abstract
Warfarin is an oral anticoagulant with significant interpatient variability in dosage. A large number of studies have confirmed that the individual warfarin dose is mainly affected by the cytochrome P450 complex subunit 2C9 and vitamin K epoxide reductase complex subunit 1. However, the association between cytochrome P450 4F2 (CYP4F2) gene polymorphisms and warfarin dosage in the Asian population remains controversial. To investigate the impact of the CYP4F2 polymorphism rs2108622 (p.V433M) on warfarin dose requirement, a systematic review and meta-analysis were conducted. According to the strict inclusion and exclusion criteria set, a comprehensive literature search was performed, and the studies published before August 5, 2015 were searched for in PubMed, EMBASE and the China National Knowledge Infrastructure databases. The references were checked by two independent reviewers. The association between the warfarin maintenance dose and CYP4F2 polymorphism was analyzed. Twenty-two studies were included in the meta-analysis. Compared with the CYP4F2 genotype CC, carriers of the CT and TT genotypes required a 9 [95% confidence interval (CI): 6.0-13.0] and 20% (95% CI, 13.0-27.0) higher warfarin dose, respectively. In the combined analysis, T carriers (CT+TT) required an 11% (95% CI, 8.0-14.0) higher warfarin dose compared to the CC genotype. In addition, there was a 10% (95% CI, 5.0-15.0) higher warfarin dose in TT carriers compared to the CT genotype (all P<0.05). The results of the meta-analysis suggest that the effects of the CYP4F2 polymorphism on individual warfarin dose have a statistically significant difference, and the effect degree is variable in the subgroups. Further studies are expected to explore whether the pharmacogenetics model including the CYP4F2 polymorphism can strengthen the prediction of warfarin dose.Keywords
This publication has 30 references indexed in Scilit:
- Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in chinese valve replacement patientsJournal of Cardiothoracic Surgery, 2012
- Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-AnalysisPLOS ONE, 2012
- CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjectsJournal of Clinical Pharmacy & Therapeutics, 2011
- CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacementBritish Journal of Clinical Pharmacology, 2010
- CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M VariantMolecular Pharmacology, 2009
- Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patientsPharmacogenetics and Genomics, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataThe New England Journal of Medicine, 2009
- CYP4F2 genetic variant alters required warfarin dosePublished by American Society of Hematology ,2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Estimation of Warfarin Maintenance Dose Based on VKORC1 (−1639 G>A) and CYP2C9 GenotypesClinical Chemistry, 2007